VivoSeq
Other

Hemangioma

21

Pipeline Programs↗

2

Active Trials↗

13

Companies Involved↗

Hemangioma is an emerging landscape with 21 programs across 13 companies. The most active players are Eli Lilly, SpyGlass Pharma, Inc., Graceway Pharmaceuticals, LLC. 8 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

66/100

Attrition Rate

27/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 2S

SpyGlass Pharma, Inc.

1 program

Phase 2G

Graceway Pharmaceuticals, LLC

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 3P

Promius Pharma, LLC

1 program

Phase 3C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

97%

Small molecule

28 of 29 classified programs — the dominant modality here.

3%ALL OTHERSProtein / enzyme13%

Small molecule leads; the ring shows all 29 classified programs, each share of the total. Modality classified for 100% of 29 pipeline programs.

Analysis

Trial Status

37

clinical trials

Completed19 · 51%
Terminated9 · 24%
Unknown status5 · 14%
Recruiting2 · 5%
No longer available1 · 3%
Withdrawn1 · 3%

Clinical Trials

Trial Activity

37 trials

A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
Recruiting·MMassachusetts General Hospital·N/A·NCT01873131·126 enrolled
Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma
Recruiting·WWest China Hospital·Phase 2/3·NCT06798363·40 enrolled
A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy
Completed·SSt. Justine's Hospital·Phase 2·NCT00601016·18 enrolled
Off Label Use of Propranolol for Infancy Hemangiomas
Completed·HHannover Medical School·N/A·NCT01211080·72 enrolled
Randomized Study of Hormonal Regulation of Infantile Hemangioma
Completed·FFDA Office of Orphan Products Development·N/A·NCT00004436·30 enrolled
Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy
Completed·—·Phase 2/3·NCT01056341·512 enrolled
The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma
Completed·SSeoul National University Hospital·Phase 4·NCT01908972·34 enrolled
Pulse Steroids Versus Oral Steroids in Problematic Hemangiomas of Infancy
Completed·TThe Hospital for Sick Children·Phase 3·NCT00312520·20 enrolled
Systemic Propranolol for the Treatment of Paediatric Patients With Infantile Hemangiomas
Completed·QQilu Hospital of Shandong University·N/A·NCT04651049·128 enrolled
Low-Dose Propranolol and Bleomycin for Infantile Hemangioma (IH)
Completed·WWuhan Integrated Traditional Chinese and Western Medicine Hospital·N/A·NCT07104526·260 enrolled
Role of Propranolol as Compared to Bleomycin in Management of Hemangioma
Completed·SShaheed Zulfiqar Ali Bhutto Medical University·N/A·NCT05327309·90 enrolled
Nadolol Versus Propranolol in Children With Infantile Hemangiomas
Completed·TThe Hospital for Sick Children·Phase 3·NCT02505971·74 enrolled
Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma
Completed·WWest China Hospital·Phase 3·NCT02342275·377 enrolled
Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)
Completed·—·Phase 2·NCT02913612·105 enrolled
Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo
Completed·—·Phase 2·NCT01512173·82 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)